by admin | Apr 19, 2024 | Article
March 6, 2024 – Lupus Canada is pleased to share that Saphnelo has been listed in Nova Scotia effective March 1, 2024. The public notice and listing criteria will appear on the Nova Scotia Pharmacare Programs website when the March Bulletin is...
by admin | Apr 19, 2024 | Article
March 10, 2024 – Lupus Canada is pleased to share that Saphnelo has been listed in Manitoba effective April 1, 2024. For more information, please visit https://www.gov.mb.ca/health/mdbif/docs/bulletins/bulletin131.pdf
by admin | Apr 19, 2024 | Article
February 1, 2024 – Benlysta, a prescription drug used to treat adults with lupus as well as adults with lupus-related kidney inflammation (active lupus nephritis), has been included in the latest update of RAMQ’s list of medications published on February 1, 2024....
by admin | Apr 19, 2024 | Article
February 15, 2024 – Lupus Canada is honoured to be a member of the CIAN group. Together our goal is to protect more Canadians to improve the quality of life and significantly reduce hospitalization for vulnerable people. On page 60 of the Heal Canada Digital...
by admin | Apr 18, 2024 | Article
Let’s Talk Lupus and Men Roundtable Living with lupus can be isolating, especially as it is generally referred as an invisible disease. Lupus can affect anyONE at anyTIME in their lives and as such it is our hope to bring awareness and inclusivity to lupus. Men...
